Avacopan for ANCA-associated vasculitis
Treatments studied
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a new diagnosis or a relapse of a type of vasculitis called GPA or MPA, and your doctor says you need treatment with cyclophosphamide or rituximab.
- You have tested positive for anti-PR3 or anti-MPO antibodies (now or in the past).
- You have active disease symptoms as measured by a scoring system, such as kidney problems or other organ involvement.
- Your kidney function is at least a certain level (eGFR 15 or higher).
- You have not had certain other autoimmune diseases, recent serious infections, or certain medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
This trial tests a new way to deliver avacopan—a drug that reduces inflammation in rare blood vessel diseases (ANCA-associated vasculitis)—through a feeding tube instead of by mouth. The study measures how much of the drug reaches your bloodstream and checks if it's safe for patients with very severe disease who are on a breathing machine.
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
This trial tests a new medicine called NM8074 for a type of blood vessel inflammation called ANCA-associated vasculitis. It's for people whose vasculitis is active and needs a stronger treatment like cyclophosphamide or rituximab.
Hear when a new Antineutrophil Cytoplasmic Antibody-associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.